Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Mehr anzeigen
Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.24 | -12.6315789474 | 1.9 | 1.97 | 1.655 | 174373 | 1.75268047 | CS |
| 4 | -0.1067 | -6.03950868852 | 1.7667 | 2.0397 | 1.65 | 138757 | 1.81698405 | CS |
| 12 | 0.62 | 59.6153846154 | 1.04 | 2.45 | 0.9691 | 527722 | 1.54645378 | CS |
| 26 | 0.918 | 123.71967655 | 0.742 | 2.45 | 0.5116 | 371216 | 1.28938249 | CS |
| 52 | 0.34 | 25.7575757576 | 1.32 | 2.45 | 0.5116 | 230085 | 1.23371833 | CS |
| 156 | -8.59 | -83.8048780488 | 10.25 | 10.58 | 0.5116 | 455563 | 2.05931832 | CS |
| 260 | -61.63 | -97.3771527888 | 63.29 | 121.98 | 0.5116 | 458027 | 13.20174181 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
